Meeting the Challenge of Pain Management in an Ever-Evolving Opioid Epidemic - Final Assessment

Launch Date:
January 20, 2022
Return to Enrollment Page

Primary Audience:

All providers eligible to prescribe opioid analgesics, including allopathic and osteopathic physicians, dentists and oral surgeons, physician assistants, nurse practitioners, pharmacists, and nurses and nurses involved in the care of patients receiving treatment for pain.

OVERVIEW

This Final Assessment will complete the Self Study section.

LEARNING OBJECTIVES

1.
Describe the scope and burden of chronic pain and opioid use disorder (OUD) in the United States 
2.
Assess patients in pain and set goals for pain management and functionality
3.
Evaluate the range of therapeutic options for managing pain, including nonpharmacological and pharmacological therapies (non-opioid and opioid analgesics)
4.
Integrate opioid analgesics into an acute pain treatment plan individualized to the needs of the patient
5.
Counsel patients and caregivers about the use of naloxone for opioid overdose
6.
Safely and effectively manage patients on opioid analgesics for the treatment of chronic pain
7.
Analyze potential benefits with the risks of serious adverse outcomes when initiating, titrating, and discontinuing use of opioids
8.
Utilize safe opioid practices pursuant to evolving federal and state regulations and expert guidelines on treating pain and prescribing opioids
9.
Identify patients who may warrant referral to specialist care
10.
Counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal
11.
Outline evidence-based strategies for treatment of opioid use disorder (OUD) 

GENERAL INFORMATION

ACCREDITATION STATEMENTS

 

Accreditation Council for Continuing Medical Education (ACCME) Accreditation Statement

MedicusCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

MedicusCME designates this Other activity (collaborative, small group social-learning model) for a maximum of 4.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center (ANCC) and the Ohio Nurses Association.

This nursing continuing professional development activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)

Activity ID: 2020-0000000317 has received ONA approval for 3.50 contact hours

Approval valid through 06/23/2022 

HOW TO CLAIM CREDIT

In order to receive CE credit and ANCC contact hours, participants must do the following:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity, review course content and learning strategies, resources and support materials provided.
  • Complete the post-test and activity evaluation.
  • You must score with an 75% or higher on the post-test to receive credit for this activity.
  • CE credit for additional disciplines is under considerataion.  All participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE FORMAT/MEDIUM: Internet Activity (Enduring Material)

ESTIMATED TIME TO COMPLETE:  4.5 hours

ACKNOWLEDGEMENTS
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

MedicusCME represents that the Program shall conform to and comply with the AMA Ethical Opinions 8.061 (Gifts to Physicians from Industry) and 9.011 (Ethical Issues in CME) and the pharmaceutical Research and Manufacturers Association Code on Interactions with Healthcare Professionals.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MedicusCME’s POLICY ON CONFLICT OF INTEREST

It is the policy of MedicusCME to identify and resolve any potential conflicts of interest of anyyone who may be in a position to influence or control the content of an education activity, to assure balance, independence, objectivity and scientific rigor in all of its accredited activities. All faculty and planners are expected to disclose all financial relationships with a commercial interest within the past twelve months.

CONFLICT OF INTEREST DISCLOSURES

Dr. Timothy Wiegand acknowledges receipt of honoraria from Braeburn Pharmaceuticals and Titan Pharmaceuticals for his role as consultant.

All other members of the Faculty Content Team, authors and planners, and the Expert Content Reviewer of this accredited activity deny any personal or financial relationships with ACCME-defined ineligible companies that may constitute any real or perceived conflict of interest.

All financial relationships are thoroughly vetted and mitigated according to MedicusCME policy.